Expert Analysis

Multiple Myeloma

Source: CCO Independent Conference Coverage of the American Society of Hematology 2007 Annual Meeting*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Multiple Myeloma

Program Director: Roy A. Beveridge, MD

Faculty:

Kenneth Anderson, MD
Sagar Lonial, MD
Robert Z. Orlowski, MD, PhD

Moderator: Seema Singhal, MD

CME CREDIT INFORMATION

Release Date: 02/21/08

Expiration Date: 02/20/09

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.4 Nursing CE credits

Pharmacists: 1.4 contact hours (0.14 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the use of the novel agents thalidomide, lenalidomide, and bortezomib in first-line treatment of patients eligible for stem cell transplantation
Review the efficacy of adding novel agents to melphalan/prednisone combinations in patients ineligible for stem cell transplantation
Summarize how various combination therapies affect stem cell mobilization
Explain the relevance of molecular remission to disease response assessment
Discuss the potential role of new agents in the treatment of relapsed or refractory multiple myeloma

Topics covered include:

Lenalidomide Plus Either Low-Dose or High-Dose Dexamethasone in Newly Diagnosed Multiple Myeloma
Lenalidomide Plus High-Dose Dexamethasone vs Dexamethasone Alone for Newly Diagnosed Multiple Myeloma
Bortezomib/Thalidomide/Dexamethasone vs Thalidomide/Dexamethasone as First-Line Treatment in Multiple Myeloma
Bortezomib/Dexamethasone Induction Therapy vs VAD in Newly Diagnosed Multiple Myeloma
First-Line Treatment Choices in Clinical Practice
Plerixafor for CD34+ Mobilization in Patients With Multiple Myeloma Undergoing ASCT
Melphalan/Prednisone/Thalidomide Improves Survival vs Melphalan/Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma
Thalidomide/Dexamethasone vs Melphalan/Prednisone in Elderly Patients With Treatment-Naive Multiple Myeloma
Bortezomib/Melphalan/Prednisone vs Melphalan/Prednisone in Patients With Treatment- Naive Multiple Myeloma
Treatment Choices in Clinical Practice for the Elderly
Molecular Remissions With Consolidation Bortezomib/Thalidomide/Dexamethasone in Patients With Multiple Myeloma Postautograft
Phase I Trials of Salvage Therapy with Carfilzomib
Additional Novel Approaches

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.